Orforglipron vs Semaglutide
Both are now approved: one a weekly injection with a cardiovascular outcomes trial behind it, the other a once-daily pill whose case rests on access, not peak efficacy.
Short answer
On weight loss, semaglutide comes out ahead, with 14.9% at 68 weeks in STEP 1 against 11.2% at 72 weeks in ATTAIN-1 for orforglipron. Those figures come from separate trials, not a head-to-head study. Both are FDA-approved. Orforglipron is taken by mouth once a day, while semaglutide is injected once a week.
Orforglipron
~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.
Full Orforglipron evidence reviewSemaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewOrforglipron vs Semaglutide: head to head
- FDA status / approved use
Orforglipron
FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under reviewSemaglutide
FDA-approved- Marketed for
Orforglipron
Weight loss, type-2 diabetesSemaglutide
Weight loss, type-2 diabetes- Outcome areas
Orforglipron
Weight loss / appetite; Blood sugar / insulin sensitivitySemaglutide
Weight loss / appetite; Blood sugar / insulin sensitivity- Evidence grade
Orforglipron
FDA-approvedSemaglutide
FDA-approved- How it works
Orforglipron
Small-molecule, non-peptide GLP-1 receptor agonist that survives digestionSemaglutide
GLP-1 receptor agonist- Route and dosing
Orforglipron
Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerabilitySemaglutide
Subcutaneous, once weekly (Wegovy label); maintenance 2.4 mg (recommended) or 1.7 mg once weekly- Headline human result
Orforglipron
11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily)Semaglutide
14.9% mean weight loss vs 2.4% on placebo at 68 weeks (STEP 1, 2.4 mg weekly)- Strongest evidence
Orforglipron
ATTAIN-1, NEJM 2025Orforglipron evidence reviewPubMed 40960239Semaglutide
STEP 1, NEJM 2021Semaglutide evidence reviewPubMed 33567185- Key safety signal
Orforglipron
Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yetSemaglutide
Nausea, vomiting and constipation, mainly when the dose is raised too quickly- How it is obtained
Orforglipron
Prescription drugSemaglutide
Prescription. Manufacturer self-pay for Wegovy (injection pen) runs $349–$399 per fill, against a $1,349 list priceWegovy cost breakdown
| Orforglipron | Semaglutide | |
|---|---|---|
| FDA status / approved use | FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under review | FDA-approved |
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Outcome areas | Weight loss / appetite; Blood sugar / insulin sensitivity | Weight loss / appetite; Blood sugar / insulin sensitivity |
| Evidence grade | FDA-approved | FDA-approved |
| How it works | Small-molecule, non-peptide GLP-1 receptor agonist that survives digestion | GLP-1 receptor agonist |
| Route and dosing | Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerability | Subcutaneous, once weekly (Wegovy label); maintenance 2.4 mg (recommended) or 1.7 mg once weekly |
| Headline human result | 11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily) | 14.9% mean weight loss vs 2.4% on placebo at 68 weeks (STEP 1, 2.4 mg weekly) |
| Strongest evidence | ATTAIN-1, NEJM 2025Orforglipron evidence reviewPubMed 40960239 | STEP 1, NEJM 2021Semaglutide evidence reviewPubMed 33567185 |
| Key safety signal | Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet | Nausea, vomiting and constipation, mainly when the dose is raised too quickly |
| How it is obtained | Prescription drug | Prescription. Manufacturer self-pay for Wegovy (injection pen) runs $349–$399 per fill, against a $1,349 list priceWegovy cost breakdown |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Our verdict
Both can be prescribed — orforglipron was FDA-approved for weight management in 2026 as Foundayo — but semaglutide has by far the deeper evidence base, with STEP 1 plus the SELECT cardiovascular result. On weight, semaglutide reported about 14.9% in STEP 1 against roughly 11% for orforglipron in ATTAIN-1, though those come from separate trials and were not compared directly. Orforglipron's real argument is form: a non-peptide small molecule taken as a once-daily tablet with no food or water restrictions. It has no long-term cardiovascular or renal outcomes data yet, and its type-2 diabetes indication is still under review.
Orforglipron fits if
You want a GLP-1 you can swallow rather than inject, with no food or water timing rules, and you accept a shallower outcomes record for that convenience.
Semaglutide fits if
You want a GLP-1 available now, with pivotal weight-loss trials and a dedicated cardiovascular outcomes trial behind it.
Orforglipron vs Semaglutide: common questions
- Are orforglipron and semaglutide both FDA-approved?
- Yes. Orforglipron was FDA-approved in April 2026 as Foundayo for chronic weight management; diabetes indication still under review. Semaglutide is FDA-approved.
- Which has stronger human evidence, orforglipron or semaglutide?
- Neither clearly. Both have approval-level evidence. The key source for orforglipron is ATTAIN-1, NEJM 2025; for semaglutide, it is STEP 1, NEJM 2021.
- What are the main safety concerns with orforglipron and semaglutide?
- For orforglipron, watch for dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet. For semaglutide, watch for nausea, vomiting and constipation, mainly when the dose is raised too quickly.
Key studies behind each
Orforglipron
- Frias JP, Hsia S, Eyde S, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. PubMed 37369232
- Wharton S, et al. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with cardiometabolic improvements. Cardiovasc Diabetol. PubMed 40481478
- Rosenstock J, Frias JP, Rodbard HW, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. PubMed 40544435
- Wharton S, Aronne LJ, Wadden TA, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. PubMed 40960239
Semaglutide
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
- Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. PubMed 33755728
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PubMed 37952131
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
The full evidence reviews
- Orforglipron: the oral non-peptide GLP-1, and what the trials actually show
A once-daily small-molecule GLP-1 pill with no food restrictions — from Phase 2 proof of concept to the Phase 3 read-outs. The evidence, graded.
Updated August 2026
- What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.
Updated August 2026